x min read

5 Stocks Under Wall Street's Radar: Texas Instruments Inc. (NASDAQ:TXN), Yahoo! Inc. (NASDAQ:YHOO), The Boeing Company (NYSE:BA), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)

5 Stocks Under Wall Street's Radar: Texas Instruments Inc. (NASDAQ:TXN), Yahoo! Inc. (NASDAQ:YHOO), The Boeing Company (NYSE:BA), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)
Written by
Alex Carlson
Published on
October 13, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Texas Instruments Inc (NASDAQ:TXN) announced on 8th October that it has released new products to increase its bouquet of offerings under the analog-to-digital converter (ADC) portfolio. The new devices are being positioned to cater to the growing demand for ADC Devices in the high voltage category. Texas Instruments Inc. (NASDAQ:TXN) in last trading activity moved down -7.13% to close at $42.74. Company weekly performance is -8.71% while its quarterly performance stands at -12.63%. Texas Instruments Inc. (NASDAQ:TXN) is -13.71% away from its 52 week high.Susquehanna reissued their neutral rating on shares of Yahoo! Inc (NASDAQ:YHOO) in a research report sent to investors on Friday morning. The firm currently has a $41.00 price target on the stock, up from their previous price target of $36.00. On last trading day Yahoo! Inc. (NASDAQ:YHOO) moved down -3.65% to close at $39.60. Its volatility for the week is 1.93% while volatility for the month is 3.20%. YHOO's sales growth for past 5 years was -8.30% and its EPS growth for past 5 years was 34.20%. Yahoo! Inc. (NASDAQ:YHOO) monthly performance is -4.02%.The Boeing Company (NYSE:BA) agreed to pay the federal government $23 million Friday to settle a case of allegedly submitting false claims for labor charges at their San Antonio location, a suit that was brought by four whistle blowers and former employees. The Boeing Company (NYSE:BA) has 0.08% insider ownership while its institutional ownership stands at 75.00%. In last trading activity company's stock closed at $121.50.On October 9, Cyclacel Pharmaceuticals, Inc (Nasdaq:CYCC) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. On Friday shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) closed at $2.83. Company's sales growth for last 5 years was 4.10%.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.